Navigation Links
Hanger Orthopedic Group, Inc. Reports $0.26 Pro Forma EPS on 8.6% Sales Growth for the Fourth Quarter 2008
Date:2/10/2009

n in the prior year due principally to the sales increase. Selling, general and administrative expenses increased by $19.3 million primarily the result of $4.1 million of personnel costs, $2.9 million of merit pay increases to employees, $3.3 million of benefits costs, $3.7 million related to acquisitions, $3.1 million in variable compensation accruals, and $2.1 million of additional investment in growth initiatives.

Interest expense for the year ended December 31, 2008 decreased $4.4 million, or 12.0%, from the prior year due to lower variable rates. For the year ended December 31, 2008, pro forma net income applicable to common stock was $27.2 million, or $0.86 per diluted share, a 34.4% increase, compared to net income applicable to common stock of $17.6 million, or $0.64 per diluted share, last year. The pro forma results for the year ended December 31, 2008 assume that the one-time, in-kind preferred stock dividend, which occurred in the second quarter of 2008, occurred at the beginning of the period and excludes the impact of the $0.7 million non-cash mark-to-market adjustment related to interest rate swaps. Net income applicable to common stock on a GAAP basis, which includes the full impact of the $5.3 million one-time non-cash dividend, the $0.4 million of preferred stock dividends and the $0.7 million impact of the non-cash mark-to-market adjustment related to interest rate swaps, was $21.1 million, or $0.78 per diluted share, for the year ended December 31, 2008.

Cash flow from operations was $18.4 million in the fourth quarter of 2008, a $3.0 million decrease, compared to $21.4 million in the prior year. The decrease in cash flow for the fourth quarter of 2008 was primarily the result of an increase in working capital of $8.5 million, offset by higher net income and non-cash charges of $5.5 million. For the year ended December 31, 2008 cash flow from operations increased by $1.5 million to $53.2 million compared to
'/>"/>

SOURCE Hanger Orthopedic Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007
2. Infor-Med, Inc. Announces New Praxis EMR Version 4 with The Praxis Knowledge Exchanger(R)
3. Hanger Orthopedic Group, Inc. Announces Three Acquisitions Totaling Over $3.5 Million of Annual Net Revenue
4. Hanger Orthopedic Group, Inc. Announces 2007 Year-End Earnings Release Conference Call
5. Hanger Orthopedic Group, Inc. Announces Senior Leadership Succession Plan and Reaffirms Guidance
6. Hanger Orthopedic Group, Inc. Announces an 11% Sales Increase and a 35% Increase in EPS to $0.23 for the Quarter Ended December 31, 2007, Compared to $0.17 in the Prior Year
7. Hanger Orthopedic Group, Inc. Announces Second Quarter 2008 Earnings Release Conference Call
8. Hanger Orthopedic Group, Inc. Receives Positive Outlook from Standard & Poors Rating Services
9. Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income
10. Hanger Orthopedic Group, Inc. Receives Positive Outlook from Moodys Investors Service
11. Hanger Orthopedic Group, Inc. Announces Underwritten Public Offering by Shareholder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Salt Lake City,Utah (PRWEB) March 05, 2015 ... that manufactures microFET medical dynamometers, ergoFET physical ... acquisition systems with sensors for ergonomics, engineering, ... new microFET Digital Handgrip Dynamometer, available at ... Handgrip was designed to offer healthcare professionals ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Building on ... with timely, relevant information, The Academy of Oncology Nurse ... titled, CONQUER: the patient voice ™ (CONQUER ™). ... affects millions of people and their loved ones each ... of AONN+. “More than ever, there is a need ...
(Date:3/5/2015)... Saint John, New Brunswick (PRWEB) March 05, 2015 ... board to help validate product innovations as the company ... advisory board will be comprised of individuals in the ... approach to working with our clients,” said Elandas CEO ... to grow as a successful organization through our collaborative ...
(Date:3/4/2015)... 04, 2015 MyCpapStore.com, an online provider ... that they sell quality products designed to remedy the ... company obtains its merchandise from name-brand manufacturers, giving its ... good performance. , Sleep apnea is a common condition ... by reduced or restricted airflow. The CPAP (continuous positive ...
(Date:3/4/2015)... UK (PRWEB) March 05, 2015 ... clinical therapeutics landscape over the past decade. The ... carriers for drug delivery in the form of ... delivering manifold drugs with more safety and efficiency. ... nanoparticles could perhaps rely greatly upon the enhanced ...
Breaking Medicine News(10 mins):Health News:New Handgrip Strength Tester Receives Rave Reviews At Physical Therapy Conference 2Health News:The Academy of Oncology Nurse & Patient Navigators Launches CONQUER: the patient voice™ to Help Meet the Informational Needs of Patients with Cancer 2Health News:Elandas Creates Advisory Board to Help Guide Innovation 2Health News:Sleep Apnea Machines CPAP and BiPap Machines Now Available for Sale 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 3
... SACRAMENTO, Calif., Aug. 8 With the fall ... to offer low-cost,physical exams at its six Sacramento area ... student-athletes, who are required to have a sports physical,in ... during the entire,month of August. It is not necessary ...
... transmission and the degree to which people are able to ... hope, have been overlooked in policies to tackle HIV/AIDS. ... (ESRC) argues that hope is a powerful tool in the ... years into the AIDS epidemic a medical vaccine for the ...
... Aug. 7 Eastern Insurance,Holdings, Inc. (Nasdaq: ... today that,it has executed a definitive agreement ... ("Employers") in a transaction valued at,approximately $14.9 ... in,debt. Employers, wholly owned subsidiary is Employers ...
... activities fostering total health in ... communities ... and Pasadena,Forward, a Pasadena-based nonprofit organization, today announced that,Kaiser Permanente ... inaugural race, calendared for Sunday, November 16, 2008, is,the flagship ...
... MEXICO CITY, Aug. 7 GlaxoSmithKline (NYSE:,GSK) ... clinical trials found,that anti-HIV regimens containing EPZICOM ... regardless of baseline viral loads.,One of the ... treatment with,regimens containing EPZICOM versus regimens containing ...
... interventions to control body,s attack on its own healthy tissue ... be more responsible for causing autoimmune diseases like lupus or ... , The finding, published in the Aug. 7 online ... a new path to pursue in finding ways to stop ...
Cached Medicine News:Health News:Sutter Express Care Offers Low-Cost Physicals for Student-Athletes 2Health News:Hope: An overlooked tool in the battle against HIV/AIDS 2Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 2Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 3Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 4Health News:Kaiser Permanente Becomes Presenting Sponsor for Pasadena Marathon 2Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 2Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 3Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 4Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 5Health News:Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral Loads 6
(Date:3/4/2015)... 2015 GSI Group Inc. (NASDAQ: ... leader and supplier of precision photonics and motion control ... industrial technology markets, today reported financial results for the ... all financial results in this press release are GAAP ... the fourth quarter of 2014, GSI generated revenue of ...
(Date:3/4/2015)... March 4, 2015  NxStage Medical, Inc. (Nasdaq: ... announced that Jeffrey H. Burbank , Chief Executive Officer, ... Miami, FL on Wednesday, March 11 ... of the event will be made available at http://ir.nxstage.com ... About NxStage NxStage Medical, Inc. (Nasdaq: ...
(Date:3/4/2015)... 4, 2015 XBiotech announced today that ... patients with moderate to severe plaque psoriasis have ... II trial evaluated the potential benefit of MABp1, ... interleukin-1 alpha (IL-1a). IL-1a is a pro-inflammatory cytokine ... skin lesions. The Company claims that blockade of ...
Breaking Medicine Technology:GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 2GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 4GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 5GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 6GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 7GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 8GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 9GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 10GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 11GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 12GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 13GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 14GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 15GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 16GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 17GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 18GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 19GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 20GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 21GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 22GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 23GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 24GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 25GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 26GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 27GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 28GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 29GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 30GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 31GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 32GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 33NxStage to Present at the Barclays Capital Global Healthcare Conference 2XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2
... , BOSTON, Dec. 30 Solos Endoscopy, Inc. (Pink ... to a prosperous 2010, following a solid year in 2009, due ... the closing months of 2009, Solos Endoscopy, Inc. has taken the ... of surgical endoscopy instruments. This will allow the MammoView(TM) line to ...
... NEW HAVEN, Conn., Dec. 30 VION PHARMACEUTICALS, INC. ... the U.S. Food and Drug Administration ("FDA") had responded to ... III randomized trial HOVON AML 92 sponsored by the Dutch-Belgian ... Onrigin(TM). The FDA raised concerns with the HOVON trial design ...
Cached Medicine Technology:Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010 2Vion Pharmaceuticals Announces FDA Conclusion 2Vion Pharmaceuticals Announces FDA Conclusion 3
... CX5 Delta takes the automation and ... and adds the benefit of electrolyte ... chemistry system for the low- to ... capabilities and continuous sample loading. The ...
... Designed for the high-volume lab, the SYNCHRON ... process- performing up to 2,880 tests per ... of the SYNCHRON LX4201 with broad menu, ... what you've come to expect from Beckman ...
... total of 53 on-board assays, an ... a host of performance-driven features, the ... workstations and automate time-intensive manual processes.The ... Immunoassay system and DL2000* intergrate to ...
The leading fully automated system for plasma protein determinations. Third generation nephelometer combines reliability with highly cost-effective performance....
Medicine Products: